Fritextsökning
Innehållstyper
-
Sobi announces agreement with Enable Injections
Swedish biopharma Sobi has entered into an international development and distribution agreement with US drug delivery company Enable Injections.
-
ZEISS Insights: Measurement of bone plates and screws
Get free access to technical paper.
-
“What is important is to create an overview and understanding from different perspectives”
Scientist Jochen Schwenk analyses blood proteins using proteomics to improve our understanding of disease and health. This year, he is moderating the Lab & Diag...
-
Forskaren in Hagastaden now inagurated
The real estate company Vectura's life science center in Hagastaden, Forskaren, is now inaugurated. The opening was attended by people from the industry, politi...
-
Level up your medical expertise
Learn from innovative industry speakers from leading MedTech companies at ZEISS Quality Innovation Days.
-
Ozempic may benefit hip replacement surgery
The high-profile drug for type 2 diabetes and weight loss may be beneficial in other areas. One such area is for patients undergoing hip replacement surgery, a new study suggests....
-
Suing the company – for NOT developing a new HIV drug
Was Gilead putting a steady flow of profits from its cash cow ahead of developing a new and safer drug? According to a large number of US HIV patients in a lega...
-
Save the dates: ZEISS Quality Innovation Summit, October 22-24
Embark on a journey to the future of metrology.
-
Explore the latest trends and innovations in quality assurance and manufacturing
ZEISS QUALITY INNOVATION SUMMIT in Berlin, October 22-24, 2024.
-
ZEISS receives FDA clearance for INTRABEAM 700
With its new treatment platform for intraoperative radiotherapy, ZEISS is actively shaping the medical innovation of neuro tumor therapy.
-
ProPharma
-
Study names with an attitude – more important than you might think
Ironman, T-rex, Star-Trek. Popcorn, Proper, Scout. Nope, these are neither fantasy films nor dog names. They’re the names of ongoing cancer studies in Sweden.
-
Dödsstraff yrkas för mordet på amerikansk vård-vd
Åklagarsidan kommer att yrka på dödsstraff för Luigi Mangione, som står inför rätta för mordet på sjukvårdsförsäkringsbolaget United Healths vd Brian Thompson i New York i fjol....
-
Are you ready for EMC 2024?
Visit ZEISS at Europe’s largest Event dedicated to Microscopy and Imaging.
-
Final assembly inspection of medical plastics
Technical paper by ZEISS Medical Industry Solutions.
-
AZ gets approval for drug targeting rare disease – it may reduce cortisone dependence
AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.
-
CTC Clinical Trial Consultants AB
-
Come see us at the upcoming events!
We have some upcoming events where you can see our latest products live!
-
A new malaria vaccine offers hope but much more research is still needed
There has long been no vaccine against malaria, but there have been breakthroughs in recent years. However, it is still unclear how we become immune to the mala...
-
What will be the next big hype after obesity? – An expert panel highlighted their top picks
What will be the next big trend in life science? Everything from Alzheimer’s, Crispr and Omics were highlighted when the issue was debated at this year’s major ...
-
Quality Assurance for the Highest Medical Standards
Metrology Solutions for Medical Components.
-
Standardisation in automation
B. Braun Melsungen had a great idea and implemented it throughout the plant. Production for infusion solutions was to be largely standardised. B. Braun hoped th...
-
Danish biotech to buy struggling American oncology company
Danish drugmaker Pharmacosmos has agreed to acquire American pharmaceutical company G1 Therapeutics in a deal that amounts to 405 million dollars.
-
Individual DNA passport could result in fewer drug side effects
You may be required to show a DNA passport when you pick up medicines at the pharmacy in the future. According to a new study, patients might suffer 30% fewer s...